Affordable Access

deepdyve-link
Publisher Website

Conditional survival estimate in patients with Barcelona Clinic Liver Cancer stage B/C hepatocellular carcinoma treated with hepatic arterial infusion chemotherapy with/without concurrent radiotherapy.

Authors
  • Cho, In Rae1, 2
  • Lee, Hye Won1, 2
  • Song, Ki Jun2, 3
  • Kim, Beom Kyung1, 2, 4
  • Kim, Seung Up1, 2, 4
  • Kim, Do Young1, 2, 4
  • Ahn, Sang Hoon1, 2, 4
  • Seong, Jinsil2, 5
  • Han, Kwang-Hyub1, 2, 4
  • Park, Jun Yong1, 2, 4
  • 1 Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea. , (North Korea)
  • 2 Yonsei Liver Center, Severance Hospital, Seoul, Korea. , (North Korea)
  • 3 Department of Biostatistics, Yonsei University College of Medicine, Seoul, Korea. , (North Korea)
  • 4 Institute of Gastroenterology, Yonsei University College of Medicine, Seoul, Korea. , (North Korea)
  • 5 Department of Radiation Oncology, Yonsei University College of Medicine, Seoul, Korea. , (North Korea)
Type
Published Article
Journal
Oncotarget
Publisher
"Impact Journals, LLC "
Publication Date
Oct 03, 2017
Volume
8
Issue
45
Pages
79914–79926
Identifiers
DOI: 10.18632/oncotarget.20321
PMID: 29108373
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

Conditional survival (CS) provides a prognosis of patients who have already survived several years after treatment. We investigated CS in Barcelona Clinic Liver Cancer (BCLC) stage B/C hepatocellular carcinoma (HCC) patients treated with hepatic arterial infusion chemotherapy (HAIC) with or without concurrent radiotherapy (CRT). A total of 181 patients diagnosed with HCC who were treated with HAIC with or without CRT between 2011 and 2015 were retrospectively reviewed. Overall survival (OS) and CS were calculated and a subgroup analysis was performed. The 1- and 5-year survival rates of all patients were 57.0% and 24.3%. OS was significantly higher in patients with BCLC stage B than BCLC stage C patients. Patients who achieved disease control after treatment also showed longer OS than who did not respond to treatment. Provided that the patient had already survived for 0, 1, 2, and 3 years, the CS estimates of surviving an additional 2 years were 35.6%, 55.1%, 82.0%, and 77.4%, respectively. A subgroup analysis was performed to compare BCLC stage B and C patients and revealed that CS has a tendency to increase and the difference in CS between two groups decreased over time. CS reflects the change of prognosis over time and may provide a more accurate prognosis and hopeful message to patients who have already survived with treatment.

Report this publication

Statistics

Seen <100 times